INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
CM
Corporate insider

Chan Mitchell

Chief Financial OfficerCIK 0001789335

EDGAR filingsOpen in network
Disclosed transactions5
Buys / sells0 / 1
Max Insider Score30
Connections with evidence2

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
30
CM
Chan MitchellDirector
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$72K
3,167 sh
May 6, 2026May 7, 2026
traded May 6, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Avalo Therapeutics, Inc.Director · Mar 31, 2026
  • Insider ofevidence
    REGENXBIO Inc.Chief Financial Officer · Jan 8, 2026
21
CM
Chan MitchellDirector
AVTXAvalo Therapeutics, Inc.
Option exercise
M
—
3,166 sh
Mar 28, 2026
Mar 31, 2026
traded Mar 28, 2026
+3d
SEC FORM 4

Evidence

21
CM
Chan MitchellDirector
AVTXAvalo Therapeutics, Inc.
Option exercise
M—
3,166 sh
Mar 28, 2026Mar 31, 2026
traded Mar 28, 2026
+3dSEC FORM 4

Evidence

21
CM
Chan MitchellChief Financial Officer
RGNXREGENXBIO Inc.
Grant or award
A—
73.7K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

9
CM
Chan MitchellChief Financial Officer
RGNXREGENXBIO Inc.
Grant or award
A—
39.6K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence